GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » EPS (Diluted)

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) EPS (Diluted) : $-0.08 (TTM As of Jan. 2020)


View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals EPS (Diluted)?

Cotinga Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Jan. 2020 was $-0.02. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2020 was $-0.08.

Cotinga Pharmaceuticals's EPS (Basic) for the three months ended in Jan. 2020 was $-0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2020 was $-0.08.

Cotinga Pharmaceuticals's EPS without NRI for the three months ended in Jan. 2020 was $-0.02. Its EPS without NRI for the trailing twelve months (TTM) ended in Jan. 2020 was $-0.08.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Cotinga Pharmaceuticals EPS (Diluted) Historical Data

The historical data trend for Cotinga Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals EPS (Diluted) Chart

Cotinga Pharmaceuticals Annual Data
Trend Apr10 Apr11 Apr12 Apr13 Apr14 Apr15 Apr16 Apr17 Apr18 Apr19
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.32 -0.30 -0.31 -0.24 -0.09

Cotinga Pharmaceuticals Quarterly Data
Apr15 Jul15 Oct15 Jan16 Apr16 Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.03 -0.02 -0.02 -0.02

Competitive Comparison of Cotinga Pharmaceuticals's EPS (Diluted)

For the Biotechnology subindustry, Cotinga Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cotinga Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cotinga Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Cotinga Pharmaceuticals's PE Ratio falls into.



Cotinga Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Cotinga Pharmaceuticals's Diluted EPS for the fiscal year that ended in Apr. 2019 is calculated as

Diluted EPS (A: Apr. 2019 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2.016-0)/21.957
=-0.09

Cotinga Pharmaceuticals's Diluted EPS for the quarter that ended in Jan. 2020 is calculated as

Diluted EPS (Q: Jan. 2020 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.408-0)/21.986
=-0.02

EPS (Diluted) for the trailing twelve months (TTM) ended in Jan. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cotinga Pharmaceuticals  (OTCPK:COTQF) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Cotinga Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire 05-22-2019